Stock Watch: Like Moths To The Unvalidated Flame
Considering Target Validation In Light Of Novartis’s Lung Cancer Failure
Leaving the validation of a drug target until the end of Phase III studies is risky, but working on the unvalidated targets identified by others is riskier still.
